Ezogabine clinical trials
Also written Retigabine, GKE-841, D-23129 and Potiga.
How each study uses ezogabine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 10 Jun 2011 · POTIGA · NDA 022345 (FDA, Drugs@FDA)
- European Union
- 27 Mar 2011 · Trobalt · EMEA/H/C/001245 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2012 (7)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 7 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 19 · Other 4
GlaxoSmithKline (16) · Xenon Pharmaceuticals Inc. (2) · James Murrough (1) · Brian Wainger (1) · Icahn School of Medicine at Mount Sinai (1) · Bausch Health Americas, Inc. (1) · University Hospital of Mont-Godinne (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ezogabine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEETerminatedPhase 3Xenon Pharmaceuticals Inc.NCT04912856Written as XEN496How we know
- XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic EncephalopathyTerminatedPhase 3Xenon Pharmaceuticals Inc.NCT04639310Written as XEN496How we know
- Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset SeizuresTerminatedPhase 4GlaxoSmithKlineNCT01721317Written as Ezogabine/Retigabine IRHow we know
- An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset SeizuresTerminatedPhase 4GlaxoSmithKlineNCT01607346Written as ezogabine/retigabineHow we know
- Study in Pediatric Subjects With EpilepsyTerminatedPhase 2GlaxoSmithKlineNCT01494584Written as ezogabine/retigabineHow we know
- Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGSTerminatedPhase 3GlaxoSmithKlineNCT01668654Written as retigabine/ezogabineHow we know
- Study to Treat Major Depressive Disorder With a New MedicationCompletedPhase 2James MurroughNCT03043560Written as EzogabineHow we know
- Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind TrialCompletedPhase 3GlaxoSmithKlineNCT00310375Written as Ezogabine: USAN Retigabine (International Nonproprietary Name)How we know
- A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset SeizuresCompletedPhase 3GlaxoSmithKlineNCT01777139Written as Retigabine IRHow we know
- Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)CompletedPhase 3GlaxoSmithKlineNCT01336621Written as Retigabine IRHow we know
- Clinical Trial of Ezogabine (Retigabine) in ALS SubjectsCompletedPhase 2Brian WaingerNCT02450552Written as EzogabineHow we know
- Study to Treat Major Depressive Disorder (MDD) With a New MedicationCompletedPhase 2Icahn School of Medicine at Mount SinaiNCT02149836Written as ezogabineHow we know
- Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097TerminatedPhase 3GlaxoSmithKlineNCT00310388Written as Retigabine (INN), Ezogabine (USAN)How we know
- Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian SubjectsWithdrawnPhase 1GlaxoSmithKlineNCT01691872Written as RetigabineHow we know
- Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset SeizuresTerminatedPhase 3GlaxoSmithKlineNCT01648101Written as Retigabine 900mg/dayHow we know
- Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese SubjectsCompletedPhase 1GlaxoSmithKlineNCT01462669Written as 50mg Ezogabine/retigabineHow we know
- An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be AssessedCompletedPhase 1GlaxoSmithKlineNCT01583036Written as Digoxin + RetigabineHow we know
- Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl MetaboliteCompletedPhase 1GlaxoSmithKlineNCT01480609Written as Retigabine / EzogabineHow we know
- Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)CompletedPhase 2Bausch Health Americas, Inc.NCT00612105Written as RetigabineHow we know
- Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in EpilepsyCompletedPhase 3GlaxoSmithKlineNCT00235755Written as RetigabineHow we know
Codes
What other systems call ezogabine · ClinicalTrials.gg INT003936
- MeSH (NLM) C101866ezogabineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 12G01I6BBUEZOGABINEConfirmed FDA, NLM, Wikidata
- RxNorm 1112990Confirmed FDA, Wikidata
- Wikidata Q2146170ezogabineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C72839EzogabineOne source FDA
- DrugBank DB04953One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C101866 | ezogabine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 12G01I6BBU | EZOGABINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1112990 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2146170 | ezogabine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C72839 | Ezogabine | One source FDA |
| DrugBank | DB04953 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.